Galactose

Overview

Galactose has been used in trials studying the treatment and diagnosis of Hepatitis C, Hepatic Cancer, Wilsons Disease, Diabetic Macular Oedema, and Focal Segmental Glomerulosclerosis, among others. There are even proposals for its use in accelerating senescence in mice, rats, and Drosophila, for its association with ovarian cancer, or even for the potential treatment of focal segmental glomerulosclerosis. Nevertheless, none of these ongoing studies have yet provided formal elucidation for their proposals. As a naturally occurring sugar, it may be found in a number dairy products. Even then, however, it is not generally used as a sweetener considering it is only about 30% as sweet as sucrose. Regardless, although it is predominantly used as a pathway to generate glucose fuel for the human body, galactose is involved as an ingredient in some commonly used vaccines and non-prescription products.

Indication

There are limited therapeutic uses for which galactose is formally indicated. Some predominant indications include (a) the use of galactose to facilitate the construction of structurally and immunologically effective attenuated vaccines , and (b) the role galactose plays as an essential element in the formation of lactulose - a synthetic disaccharide indicated for the treatment of constipation and/or hepatic encephalopathy (HE); hepatic coma . Nevertheless, there are many studies looking into a variety of possible uses for galactose, including the use of the monosaccharide sugar for accelerating senescence in mice, rats, and Drosophila , the proposed association between galactose in consumed milk and ovarian cancer , a possible role in the therapy of focal segmental glomerulosclerosis , among various others. Regardless, none of these proposed indications have yet been formally elucidated for practical use.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801)	2022/06/02	NCT05402332	Phase 2	Not yet recruiting	Eva Morava-Kozicz
AVTX-801 D-galactose Supplementation in SLC35A2-CDG	2022/06/02	NCT05402384	Phase 2	Not yet recruiting	Eva Morava-Kozicz
sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis	2016/03/09	NCT02702765	Not Applicable	Completed	University of Aarhus
Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C	2015/08/19	NCT02528461	N/A	Completed	University of Aarhus
Direct Peritoneal Resuscitation Plus Conventional Resuscitation	2013/06/20	NCT01882218	Phase 4	Withdrawn	University of Louisville
Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome	2010/04/29	NCT01113385	Not Applicable	Completed	Children's National Research Institute
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5	2009/01/01	NCT00816504	Phase 1	Withdrawn	Northwell Health
Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor	2009/01/01	NCT00816478	Phase 1	Terminated	Northwell Health
Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial	2008/12/24	NCT00814255	Phase 2	Completed	NYU Langone Health

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
LEVOVIST - PWS IV (4G GRANULES /VIAL)	berlex canada inc.	02229102	Powder For Solution - Intravenous	999 MG / G	12/19/1997
ECHOVIST	berlex canada inc.	02237356	Powder For Suspension , Kit - Intrauterine	3 G / VIAL	2/15/1999
ECHOVIST	berlex canada inc.	02237356	Powder For Suspension , Kit - Intrauterine	13.5 ML / VIAL	2/15/1999

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access